Immunome, Inc. (IMNM) – What Are Brokerages Saying About This Stock?

Shares of Immunome, Inc. (NASDAQ:IMNM) have earned a consensus rating of “Moderate Buy” from the fifteen ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $34.25.

IMNM has been the subject of several research reports. Truist Financial upped their target price on Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Alliance Global Partners started coverage on Immunome in a research note on Monday, September 21st. They set a “buy” rating and a $32.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a report on Thursday, October 15th. William Blair started coverage on shares of Immunome in a research report on Friday, October 16th. They set an “outperform” rating on the stock. Finally, Wedbush reaffirmed an “outperform” rating and issued a $35.00 price target on shares of Immunome in a research report on Tuesday, October 27th.

Insider Activity at Immunome

In other news, Director Isaac Barchas sold 62,291 shares of Immunome stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $26.23, for a total value of $1,633,892.93. Following the transaction, the director directly owned 92,211 shares in the company, valued at approximately $2,418,694.53. This trade represents a 40.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jack Higgins sold 13,200 shares of the business’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $25.32, for a total value of $334,224.00. Following the completion of the transaction, the insider directly owned 65,050 shares of the company’s stock, valued at approximately $1,647,066. The trade was a 16.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 223,368 shares of company stock valued at $5,747,142 over the last ninety days. 7.21% of the stock is owned by company insiders.

Institutional Investors Weigh In On Immunome

A number of institutional investors have recently added to or reduced their stakes in IMNM. Sterling Capital Management LLC raised its holdings in Immunome by 840.0% in the third quarter. Sterling Capital Management LLC now owns 3,478 shares of the company’s stock worth $75,000 after purchasing an additional 3,108 shares in the last quarter. GK Wealth Management LLC purchased a new stake in shares of Immunome during the third quarter valued at about $71,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Immunome during the second quarter valued at about $27,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Immunome in the 2nd quarter valued at about $576,000. Finally, Readystate Asset Management LP boosted its holdings in shares of Immunome by 23.3% in the 2nd quarter. Readystate Asset Management LP now owns 1,605,820 shares of the company’s stock valued at $34,027,000 after buying an additional 303,958 shares in the last quarter. Institutional investors own 44.58% of the company’s stock.

Immunome Price Performance

Shares of IMNM opened at $18.21 on Friday. Immunome has a 1-year low of $14.64 and a 1-year high of $30.06. The company has a 50-day moving average of $22.44 and a 200 day moving average of $22.47. The firm has a market capitalization of $2.07 billion, a price-to-earnings ratio of -7.20 and a beta of 2.55.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, August 11th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). On average, equities analysts anticipate that Immunome will post -2.48 earnings per share for the current fiscal year.

Immunome Company Profile

Immunome, Inc (NASDAQ: IMNM) is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based medicines. Its technology platform analyzes human immune responses to identify antibodies that may be developed into therapies for serious diseases.

The company’s research activities have included therapeutic programs in oncology and immunology, with an emphasis on antibodies designed to affect disease-driving biological pathways. Immunome has also conducted antibody discovery work related to infectious diseases, including SARS-CoV-2, as it has expanded its focus toward broader therapeutic applications.

Immunome is headquartered in Exton, Pennsylvania, and serves the global biopharmaceutical market through internal research and development activities and potential collaborations.